Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Henry Schein, Inc. Add to portfolio

NAS:HSIC, Jun 06, 07:07 UTC

Latest NAS:HSIC News

Filter your feed

Apply Filter

Wednesday, May 06


News

Matson (MATX) Q1 2020 Earnings Call Transcript

HSIC

We expect the fleet repositioning, operating changes, and cost management initiatives to improve operating results by $40 million to $50 million in 2020, of which two-thirds is from fleet repositioning and other operational changes. However, the financial benefits from these actions will only partially offset profit declines in our businesses as a result of the COVID-19 situation and its economic effects. These committed capital projects include the Hawaii vessel renewal program, where our fourth and final vessels are expected to be delivered in the fourth quarter. We expect the deferral and elimination of CAPEX to result in approximately $30 million in savings in 2020. While we have a rather limited ability to curtail CAPEX in 2020 due to the committed projects I mentioned, we have more flexibility to contract the capital spending in 2021 and 2022 to the extent the depth or duration of the economic cycle is more pronounced. The first is in the category of deploying our largest assets in the market that seems the most active. What's clear is Hawaii will remain muted for the time being at least. And so moving our larger vessels into the CLX where we happen to have this unprecedented level of demand given the relocation of the market will produce some of that benefit. And then we basically did a bottom-up as most companies are doing, bottom-up look at ways in which we can reduce our operating expenses in line with the lower expected levels of freight volume. And so there are, I would say, over 100 separate initiatives from every terminal, from every location, every one of our locations, which are looking at ways to reduce our operating costs. And then, of course, we're looking at deferring capital and deferring all sorts of discretionary expenditures until we get a better look at this cycle. So I would say with regard to your question about when and how they roll out a number of the initiatives that we're looking at are only get a three-quarter year or eight-month benefit. So the annual run rate of that $40 million to $50 million is actually higher. And to the extent that the economic cycle remains muted into the future, we'll have a running head start on cost reduction initiatives going into 2021 if that's necessary. So given that it was difficult for us to know exactly what was going to happen, we've decided to take a very strong firm reduction at our recurring operating expenses given the uncertainty. But we're also careful to do nothing that would create permanent damage to our services so that when the cycle ends, our whole goal is to remain effective and to be able to bounce back when that eventual recovery occurs, although, for planning purposes, we're not assuming it happens in the next nine to 12 months. But what else would you add, Joel, for that?

Read Full Details

Story Sources

fool.com fool.com
Topics:
  • Business
  • Financial
  • Health

Tuesday, May 05


News

Henry Schein (HSIC) Q1 Earnings and Revenues Top Estimates

HSIC

Excluding product sales to Covetrus under the transition services agreement related to Henry Schein’s Animal Health spin-off, internal sales growth in local currencies was 1.8%. The 3.7% internal decline in local currencies included a decrease of 3.9% in North America and a drop of 3.4% internationally.North America dental sales were in line with the company’s expectations for the first two months of the quarter. However, since March dental consumable merchandise and equipment internal sales were adversely impacted by suspension of non-emergency procedures in response to the coronavirus outbreak. Per Henry Schein, as of today, it has $201.2 million authorized and available for stock repurchases.At the end of the first quarter, net cash flow from continuing operations was $90.8 million compared with $133.3 million in the year-ago period.2020 Guidance WithdrawnThe company had initially provided its financial guidance for 2020 during its fourth-quarter earnings release on Feb 20, where it specifically noted that guidance did not assume any significant supply chain disruption related to COVID-19.However, on Apr 6, Henry Schein announced the withdrawal of the previously-announced guidance given the growing impact of COVID-19 on its business and customers. As the uncertainty of the pandemic and its impact on business operations cannot be ascertained at present, the company is not issuing any new financial guidance for the year at present.Our TakeHenry Schein exited the first quarter of 2020 with better-than-expected results despite the adversities posed by the coronavirus outbreak. The company is working to bring additional tests as well as more PPE to the market.Zacks Rank and Stocks to ConsiderHenry Schein currently has a Zacks Rank #4 (Sell).Some better-ranked stocks in the broader medical space are Aphria Inc. APHA, Biogen Inc. BIIB and Eli Lilly and Company LLY.Aphria reported third-quarter fiscal 2020 adjusted EPS of 2 cents, comparing favorably with the Zacks Consensus Estimate of a loss of 4 cents.

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, April 01


News

Henry Schein Announces Further Efforts to Address the COVID-19 Pandemic

HSIC

Henry Schein Announces Further Efforts to Address the COVID-19 Pandemic. Working with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and BioMedomics, a privately held, North Carolina-based clinical diagnostics company, Henry Schein will make the test kits available to health care professionals as part of the Company’s broad offering of point-of-care rapid tests. The agreement with BD and BioMedomics builds on Henry Schein’s announcement last week of an antibody rapid blood test, known as Standard Q COVID-19 IgM/IgG Rapid Test, which is also administered at the point of care and delivers results within 15 minutes from a pinprick with no instrumentation required. To learn more about what Henry Schein is doing to address this unprecedented situation and the actions the Company is taking to get more product into the hands of those who need it most – health care workers – please visit www.henryschein.com/COVID19update. For customers interested in more information about the antibody rapid test kits, please contact Henry Schein at (844) 211-0140.

Read Full Details

Topics:
  • Business
  • Health
  • Science

Wednesday, March 11


News

Henry Schein (HSIC) Expands by Signing JV With Casa Schmidt

HSIC

Henry Schein (HSIC) Expands by Signing JV With Casa Schmidt | NASDAQ. Notably, the dental business is a component of the company’s health care distribution arm. The company introduced the beta version of its Tech Dentrix to streamline collection procedures, curb mailing costs and boost cash flow.Henry Schein launched Dentrix G7.3 in the fourth quarter to improve insurance payment procedures. The integration of Dentrix practice management software and DEXIS via the Dentrix Smart Image will likely enable oral health professionals to further automate their practice management.Price PerformanceShares of Henry Schein have dipped 3.1% in the past year compared with the industry’s 13.5% decline.Zacks Rank & Key PicksCurrently, the company carries a Zacks Rank #3 (Hold).Some better-ranked stocks from the broader medical space are ResMed Inc. RMD, Medtronic plc MDT and Hill-Rom Holdings, Inc. HRC.ResMed has a projected long-term earnings growth rate of 14.5%.

Read Full Details

Story Sources

nasdaq.com zacks.com
Topics:
  • Business
  • Health
  • Financial

Thursday, March 05


News

Here's Why You Should Retain Henry Schein (HSIC) Stock Now

HSIC

Here's Why You Should Retain Henry Schein (HSIC) Stock Now. Henry Schein HSIC has been progressing well with product portfolio expansion and acquisitions. However, tough competition and macroeconomic uncertainty are likely to offset the positives to some extent. The company also launched Dentrix G7.3 to improve insurance payment procedures and a chairside dashboard for Dentrix Ascend in the Symbian cloud-based system, which delivers enhanced clinical patient outcomes for the dentists. Strong Guidance: The company’s adjusted earnings of $3.65 to $3.75 suggests 4-7% growth from that reported in 2019.

Read Full Details

Topics:
  • Business
  • Financial

Friday, February 21


News

Henry Schein (HSIC) Q4 2019 Earnings Call Transcript

HSIC

Before we begin, I would like to state that certain comments made during this call will include information that is forward-looking. As you know, risks and uncertainties involved in the company's business may affect the matters referred to in forward-looking statements. As a result, the company's performance may materially differ from those expressed in or indicated by such forward-looking statements. This often translates into recurring sales of these value-added services, with a higher margin profiles and accordingly, as I just noted, earnings accretion. Some acquisition highlights in 2019 included our entry into the Nordic dental market, a market we had not have presence up to now; and the expansion of our dental business in China. Gastroenterology, orthopedics and dermatology are just a few of the areas of focus. And Henry Schein has robust plans to deliver value in these growth segments. There is a lot of exciting development work going on at Henry Schein One as we continue to evolve as a service provider and trusted resource for a broad selection of products and services to, as we noted earlier on, to the various sectors of the dental market, small, mid-sized and very large practices.

Read Full Details

Story Sources

nasdaq.com fool.com
Topics:
  • Business
  • Health
  • Financial

Thursday, February 20


News

Henry Schein (HSIC) Q4 Earnings and Revenues Top Estimates

HSIC

On a reported basis, EPS from continuing operations was $2.25, showing a stupendous increase of 192.2% on a year-over-year basis primarily due to a net gain on the sale of equity investments. For 2019, adjusted EPS was $3.51, up 10.7% from the year-ago period. Henry Schein derives revenues from four operating segments — Dental, Medical, and Technology and Value-added Services. Adjusted operating income improved 1.4% year over year to $194.7 million. However, adjusted operating margin contracted 47 bps to 7.3%. It expects adjusted EPS of $3.65 to $3.75, suggesting 4-7% growth from that reported in 2019.

Read Full Details

Topics:
  • Business
  • Financial

Tuesday, February 11


News

Shareholder Alert: Robbins LLP Is Investigating Henry Schein, Inc. (HSIC) for Violating the Federal Trade Act

HSIC

Shareholder rights law firm Robbins LLP is investigating whether certain officers and directors of Henry Schein, Inc. (NASDAQ: HSIC) violated the Federal Trade Act and U.S. Henry Schein is purportedly the largest health care provider in the world. If you suffered a loss as a result of Henry Schein's misconduct, click here. Between March 2013 and February 2018, the executives of Henry Schein engaged in a conspiracy with Benco and Patterson to restrain trade to drive down competition in the dental products market and inflate the prices of dental products. This agreement included refusing to offer discounted prices or to negotiate with group purchasing organizations, refraining from poaching one another's customers or sales representatives, and blocking the entry and expansion of rival distributors.

Read Full Details

Topics:
  • Business
  • Financial

Tuesday, February 04


News

Henry Schein to Open Nasdaq in Celebration of 18th Annual Give Kids A Smile® Program

HSIC

Henry Schein, Inc. (Nasdaq: HSIC) announced that it will ring the Nasdaq Stock Market Opening Bell tomorrow in celebration of Give Kids A Smile (GKAS), an American Dental Association (ADA) initiative that provides free oral health care to children in need across the U.S. Henry Schein has partnered with the ADA to present GKAS since the program’s inception 18 years ago. "All children, regardless of their circumstances, deserve access to quality dental care and oral health education. It is rewarding to see the impact this program has made in the last 18 years, and through partnership and collaboration, we believe its best years are yet to come." Celebrated nationally on the first Friday of each February, and with events taking place year-round, GKAS is the result of a public-private partnership between the ADA, Henry Schein, and Colgate-Palmolive. Henry Schein's supplier partners that are supporting the 2020 Give Kids A Smile program through product donations include 3M, Ansell, Centrix, Colgate, Coltene, Crosstex, DASH Medical, Dentsply Sirona, DMG America, DUKAL Corporation, Medicom, Microflex, Premier, Sempermed, Septodont, SS White, Sunstar, TIDI Products, Tuttnauer USA, Young Dental, and Zirc.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Thursday, January 30


News

HR for Health and Henry Schein, Inc. Announce Exclusive Business Relationship to Provide Doctors with New Solutions to Simplify Human Resources & Payroll

HSIC

Together, Henry Schein Business Solutions, which offers dentists resources for business operations, finance, marketing, education, training and more, and HR for Health's human resources and compliance software will provide doctors with a comprehensive portfolio of solutions to help address the challenges of practice ownership, including team performance management, new patient flow, operations, payroll processing, and complying with ever-changing employment laws. "Thanks to our newly formed relationship with Henry Schein, we can help more practices achieve HR compliance and find peace of mind." Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. The Company's sales from continuing operations reached $9.4 billion in 2018, and have grown at a compound annual rate of approximately 13 percent since Henry Schein became a public company in 1995. For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, and @HenrySchein on Twitter. SOURCE HR for Health.

Read Full Details

Topics:
  • Business
  • Health
  • Financial